Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman 3rd, Zoe Diana Draelos, Derek Jones, Mitchel P Goldman, Michael L Pucci, Amanda VanDenburgh, Emily Weng, Scott M Whitcup, Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman 3rd, Zoe Diana Draelos, Derek Jones, Mitchel P Goldman, Michael L Pucci, Amanda VanDenburgh, Emily Weng, Scott M Whitcup
Abstract
Background: Eyebrow loss may have substantial negative functional and social consequences.
Objective: Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.
Methods: This multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.
Results: At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.
Conclusion: Bimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.
Conflict of interest statement
The authors have indicated no significant interest with commercial supporters.
Figures
References
- Baker SB, Dayan JH, Crane A, Kim S. The influence of brow shape on the perception of facial form and brow aesthetics. Plast Reconstr Surg 2007;119:2240–7.
- Sadr J, Jarudi I, Sinha P. The role of eyebrows in face recognition. Perception 2003;32:285–93.
- van der Velden EM, Drost BH, Ijsselmuiden OE, Baruchin AM, et al. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol 1998;37:617–21.
- Velez N, Khera P, English JC., III Eyebrow loss: clinical review. Am J Clin Dermatol 2007;8:337–46.
- Ortiz AE, Alster TS. Rising concern over cosmetic tattoos. Dermatol Surg 2012;38:424–9.
- Fitzpatrick RE, Goldman MP, Dierickx C. Laser ablation of facial cosmetic tattoos. Aesthet Plast Surg 1994;18:91–8.
- Women's Rogaine [package insert]. Skillman, NJ: Johnson & Johnson Healthcare Products; 2014.
- Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthet Plast Surg 2011;35:116–21.
- Schweiger ES, Pinchover L, Bernstein RM. Topical bimatoprost for the treatment of eyebrow hypotrichosis. J Drugs Dermatol 2012;11:106–8.
- Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J 2014;20.
- Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg 2013;39:1079–87.
- Smid SD. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: a closer look at the agonist properties of bimatoprost and the prostamides. Clin Ophthalmol 2009;3:663–70.
- Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 2008;153:410–9.
- Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, et al. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol 2010;162:1186–97.
- Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010;36:1361–71.
- Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol 2010;4:349–58.
- Fagien S. Management of hypotrichosis of the eyelashes: Focus on bimatoprost. Clin Cosmet Investig Dermatol 2010;3:39–48.
- Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005;123:1541–6.
- Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55–68.
- Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol 2014;41:149–52.
- Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol 2012;39:865–6.
- Williams RD, Cohen JS, Gross RL, Liu CC, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008;92:1387–92.
- Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg 2010;36:638–49.
- Smith S, Fagien S, Whitcup SM, Ledon F, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol 2012;66:801–6.
- Harii K, Arase S, Tsuboi R, Weng E, et al. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Aesthet Plast Surg 2014;38:451–60.
Source: PubMed